TREVENA, INC. (NASDAQ:TRVN) Files An 8-K Financial Statements and Exhibits
|99.1||Press Release dated March 12, 2020|
|99.2||Transcript of Conference Call held on March 12, 2020|
TREVENA INC Exhibit
EX-99.1 2 tm2012526d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Trevena Reports Fourth Quarter and Full Year 2019 Results — PDUFA date of August 7,…
To view the full exhibit click
About TREVENA, INC. (NASDAQ:TRVN)
Trevena Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250. Its TRV130 is a Mu-receptor G protein Pathway Selective (Mu-GPS) modulator that activates G protein. Its TRV250 is a small molecule G protein biased ligand of the d-opioid receptor in preclinical development. Its TRV734 is a small molecule Mu-GPS that it has discovered and has developed through Phase I as a first-line, orally administered compound for the treatment of moderate to severe acute and chronic pain. Its TRV027 is a peptide b-arrestin biased ligand that targets the angiotensin II type 1 receptor (AT1R). In addition to these three product candidates, the Company has identified and has completed the Phase I program for TRV734.